RT Journal Article
SR Electronic
T1 S-ketamine in patient-controlled analgesia reduces opioid consumption in a dose-dependent manner after major lumbar fusion surgery: a randomized, double-blind, placebo-controlled clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.21250352
DO 10.1101/2021.01.22.21250352
A1 Brinck, Elina C.V.
A1 Virtanen, Taru
A1 Mäkelä, Sanna
A1 Soini, Venla
A1 Hynninen, Ville-Veikko
A1 Mulo, Jukka
A1 Savolainen, Urmas
A1 Rantakokko, Juho
A1 Maisniemi, Kreu
A1 Liukas, Antti
A1 Olkkola, Klaus T.
A1 Kontinen, Vesa
A1 Tarkkila, Pekka
A1 Peltoniemi, Marko
A1 Saari, Teijo I.
YR 2021
UL http://medrxiv.org/content/early/2021/02/16/2021.01.22.21250352.abstract
AB BACKGROUND Spinal fusion surgery causes severe pain. Strong opioids, commonly used as postoperative analgesics, may have unwanted side effects. S-ketamine may be an effective analgesic adjuvant in opioid patient-controlled analgesia (PCA). However, the optimal adjunct S-ketamine dose to reduce postoperative opioid consumption is still unknown.METHODS We randomized 107 patients at two tertiary hospitals in a double-blinded, placebo-controlled clinical trial of adults undergoing major lumbar spinal fusion surgery. Patients were randomly allocated to four groups in order to compare the effects of three different doses of adjunct S-ketamine (0.25, 0.5, and 0.75 mg ml−1) or placebo on postoperative analgesia in oxycodone PCA. Study drugs were administered for 24 hours postoperative after which oxycodone-PCA was continued for further 48 hours. Our primary outcome was cumulative oxycodone consumption at 24 hours after surgery.RESULTS Of the 100 patients analyzed, patients receiving 0.75 mg ml−1 S-ketamine in oxycodone PCA needed 25% less oxycodone at 24 h postoperatively (61.2 mg) compared with patients receiving 0.5 mg ml−1 (74.7 mg) or 0.25 mg ml−1 (74.1 mg) S-ketamine in oxycodone or oxycodone alone (81.9 mg) (mean difference: −20.6 mg; 95% confidence interval [CI]: −41 to −0.20; P = 0.048). A beneficial effect in mean change of pain intensity at rest was seen in the group receiving 0.75 mg ml−1 S-ketamine in oxycodone PCA compared with patients receiving lower ketamine doses or oxycodone alone (standardized effect size: 0.17, 95% CI: 0.013–0.32, P = 0.033). The occurrence of adverse events was similar among the groups.CONCLUSIONS Oxycodone PCA containing S-ketamine as an adjunct at a ratio of 1: 0.75 decreased cumulative oxycodone consumption at 24 h after major lumbar spinal fusion surgery without additional adverse effects.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02994173Funding StatementThis work was supported by a governmental research grant from the Hospital District of South-West Finland, Finland (#13821)(T.I.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of the Hospital District of Southwest Finland (number: 103/1800/2016) and the Finnish Medicines Agency (FIMEA, KL 135/2016).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to Finnish Medical Research Act (488/1999) data cannot be made available. The corresponding author gives further information on this matter.